All In Biotech

Drug Trial Radar · NCT04796623

A Study of TQB3616 Capsules Combined With Fulvestrant Injection in Subjects With Advanced Breast Cancer

A Open-label, Multicenter Phase II Study of TQB3616 Capsules Combined With Fulvestrant Injection in Subjects With HR-positive, HER2-negative Advanced Breast Cancer

Last checked: Nov 19, 2026Latest source record: Apr 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

122

Actual

Start

Feb 4, 2021

Primary completion

May 24, 2024

Study completion May 24, 2024

Sponsor

Sponsor type
Industry
First posted
Mar 15, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a multicenter, open-label, multi-cohort phase II clinical trials to evaluate the efficacy and safety of TQB3616 capsules combined with Fulvestrant injection in subjects with HR-positive and HER2-negative advanced and/or metastatic breast cancer, including Cohort 1 and Cohort 2. Each cohort will enroll 30-60 cases.

Conditions

  • HR-positive, HER2-negative Advanced Breast Cancer

Interventions

  • TQB3616 capsulesDrug

    TQB3616 capsules 180 mg given orally, once daily in 28-day cycle.

  • Fulvestrant injectionDrug

    Fulvestrant injection was given at a fixed dose of 500mg on day 1, day 15 of the first cycle and day 1 of each subsequent cycle, and each cycle is 28 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall response rate (ORR) assessed by investigatorTime frame: Baseline up to 24 months

Locations

17 sites in 1 country. Site status is shown where the registry gives one.

  • The Fifth Medical Center of PLA General Hospital

    Beijing, Beijing Municipality, China

  • Chongqing University Cancer Hospital

    Chongqing, Chongqing Municipality, China

  • Gansu Provincial Hostipal

    Lanzhou, Gansu, China

  • Guangdong General Hospital

    Guangzhou, Guangdong, China

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, China

  • Guangxi Medical University Affiliated Tumor Hospital

    Nanning, Guangxi, China

  • The Fourth Hospital of Hebei Medical University

    Shijiazhuang, Hebei, China

  • Harbin Medical University Affiliated Cancer Hospital

    Harbin, Heilongjiang, China

  • Hunan Cancer Hospital

    Changsha, Hunan, China

  • Jiangsu Province Hospital

    Nanjing, Jiangsu, China

  • The Second Hospital of Dalian Medical University

    Dalian, Liaoning, China

  • Liaoning Cancer Hospital & Institute

    Shenyang, Liaoning, China

  • Shanghai East Hospital

    Shanghai, Shanghai Municipality, China

  • The Second Affiliated Hospital of PLA Air Force Military Medical University

    Xi’an, Shanxi, China

  • The First Affiliated Hospital of Xi'an Jiao Tong University

    Xi’an, Shanxi, China

  • Affiliated Tumor Hospital of Xinjiang Medical University

    Ürümqi, Xinjiang, China

  • The First Affiliated Hospital Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.